MedTrace Logo

ctDNA in Cutaneous Squamous Cell Carcinoma

NCT06875609 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-03-30

No results posted yet for this study

Summary

The purpose of this study is to test the potential for a liquid biopsy assay to detect residual disease after surgery in patients with cutaneous squamous cell carcinoma as well as the potential for this assay to monitor response to immunotherapy treatment.

Conditions

Interventions

DIAGNOSTIC_TEST

Blood and Tissue Collection

Blood samples, and tissue samples will be collected from the participants, and used to determine whether circulating tumor DNA (ctDNA) testing can help monitor treatment in patients with CSCC, and to determine how ctDNA levels change in patients.

Sponsors & Collaborators

  • Haystack Oncology, Inc.

    collaborator UNKNOWN

  • Massachusetts General Hospital

    collaborator OTHER

  • Massachusetts Eye and Ear Infirmary

    lead OTHER

Principal Investigators

  • Sophia Z. Shalhout, PhD · Massachusetts Eye and Ear

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-24
Primary Completion
2028-04-30
Completion
2029-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06875609 on ClinicalTrials.gov